SAN CLEMENTE, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners ...
FDA clearance supported by a clinical study (n=67) and demonstrated treatment safety and efficacy utilizing SUPERB™, 97% of the treated participants in the trial showed improvement in the appearance ...
SAN CLEMENTE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced ...
SAN CLEMENTE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced ...
FDA clearance supported by highly compelling clinical study results demonstrating 93% of subjects treated arms were “improved” or “very much improved” in appearance, following treatment utilizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback